| Current News About
gout alcohol :
An international team of researchers led by Professors Mark Caulfield and Patricia Munroe, from the William Harvey Research Institute at Barts and The London School of Medicine and Dentistry with Chris Cheeseman at the University of Alberta in Canada and Kelle Moley at the University of Washington in USA, have shown that the SLC2A9 gene, which encodes a glucose transporter, is also a high-capacity urate transporter, and thus possibly a new drug target for gout.
A fungus called microsporidia that causes chronic diarrhea in AIDS patients, organ transplant recipients and travelers has been identified as a member of the family of fungi that have been discovered to reproduce sexually. A team at Duke University Medical Center has proven that microsporidia are true fungi and that this species most likely undergoes a form of sexual reproduction during infection of humans and other host animals.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in favor of approval, with one panel member abstaining.
A study led by a team of scientists in Scotland suggests that genes may play a part in increasing one's risk of developing gout, a painful condition that affects the joints. The study is published in the 9 March online issue of Nature Genetics and is the work of researchers based at the MRC Human Genetics Unit, Western General Hospital, Edinburgh, and colleagues from other research centres in the UK and also in Croatia and Germany.
The goal in treating patients with gout is to reduce acute attacks by lowering serum urate levels, which are usually high in this disease. At the same time, high serum urate levels have been shown to lower the risk of developing Parkinson's disease (PD). A new study compared the safety and efficacy of febuxostat, a new drug being developed for gout that was recently approved for use in Europe, and a commonly used drug that has been around for years.
According to an article published early online and in an upcoming edition of The Lancet, researchers have gained new insights into the genetic properties of gout. Dr Caroline Fox (National Heart Lung and Blood Institute, Bethesda, MD, USA) and colleagues demonstrate that three genes are linked to an increased risk of gout. Well before onset of clinical symptoms, doctors can analyze a genetic risk score based on these genes to find those at highest risk of the condition.
Ipsen (Paris:IPN) announced that the European Commission granted marketing authorisation for Adenuric® (febuxostat) for the treatment of chronic hyperuricaemia in gout. Adenuric® thus pioneers the first major treatment alternative for gout, a severe debilitating disease, for more than 40 years.
Risk factors for gout include family history, older age, renal insufficiency, use of medications that reduce urate excretion, high intake of foods that increase urate production (beer, seafood, red meat, high-fructose beverages), and comorbidities such as obesity and metabolic syndrome. About 90% of acute gout attacks are monoarticular; 50% occur in the first metatarsophalangeal joint. Pain, redness, and swelling peak in 1 day.
Researchers have identified two new genes - and confirmed the role of a third gene - associated with increased risk of higher levels of uric acid in the blood, which can lead to gout, a common, painful form of arthritis. Combined, the three genetic variations were associated with up to a 40-fold increased risk in developing gout.
|
|
